Novavax PE Ratio 2006-2021 | NVAX

Current and historical p/e ratio for Novavax (NVAX) from 2006 to 2021. The price to earnings ratio is calculated by taking the latest closing price and dividing it by the most recent earnings per share (EPS) number. The PE ratio is a simple way to assess whether a stock is over or under valued and is the most widely used valuation measure. Novavax PE ratio as of September 23, 2021 is 0.00.

Please refer to the Stock Price Adjustment Guide for more information on our historical prices.

Novavax PE Ratio Historical Data
Date Stock Price TTM Net EPS PE Ratio
2021-09-23 257.30 0.00
2021-06-30 212.31 $-13.71 0.00
2021-03-31 181.31 $-9.26 0.00
2020-12-31 111.51 $-6.79 0.00
2020-09-30 108.35 $-5.22 0.00
2020-06-30 83.35 $-2.75 0.00
2020-03-31 13.58 $-4.14 0.00
2019-12-31 3.98 $-5.76 0.00
2019-09-30 5.02 $-7.23 0.00
2019-06-30 5.86 $-8.89 0.00
2019-03-31 11.02 $-9.60 0.00
2018-12-31 36.80 $-10.20 0.00
2018-09-30 37.60 $-10.80 0.00
2018-06-30 26.80 $-11.40 0.00
2018-03-31 42.00 $-12.20 0.00
2017-12-31 24.80 $-12.60 0.00
2017-09-30 22.80 $-13.60 0.00
2017-06-30 23.00 $-15.40 0.00
2017-03-31 25.60 $-18.00 0.00
2016-12-31 25.20 $-20.60 0.00
2016-09-30 41.60 $-22.20 0.00
2016-06-30 145.40 $-19.80 0.00
2016-03-31 103.20 $-15.60 0.00
2015-12-31 167.80 $-11.80 0.00
2015-09-30 141.60 $-8.60 0.00
2015-06-30 222.80 $-7.80 0.00
2015-03-31 165.40 $-7.80 0.00
2014-12-31 118.60 $-7.20 0.00
2014-09-30 83.40 $-6.00 0.00
2014-06-30 92.40 $-6.20 0.00
2014-03-31 90.60 $-6.20 0.00
2013-12-31 102.40 $-6.20 0.00
2013-09-30 63.00 $-6.00 0.00
2013-06-30 41.00 $-5.20 0.00
2013-03-31 45.60 $-4.60 0.00
2012-12-31 37.80 $-4.40 0.00
2012-09-30 43.20 $-3.80 0.00
2012-06-30 31.20 $-3.40 0.00
2012-03-31 25.20 $-3.20 0.00
2011-12-31 25.20 $-3.40 0.00
2011-09-30 32.00 $-4.00 0.00
2011-06-30 40.40 $-5.40 0.00
2011-03-31 51.80 $-6.40 0.00
2010-12-31 48.60 $-7.20 0.00
2010-09-30 43.80 $-9.00 0.00
2010-06-30 43.40 $-8.60 0.00
2010-03-31 46.20 $-8.80 0.00
2009-12-31 53.20 $-9.00 0.00
2009-09-30 79.20 $-9.00 0.00
2009-06-30 65.60 $-9.80 0.00
2009-03-31 20.40 $-10.80 0.00
2008-12-31 37.80 $-11.00 0.00
2008-09-30 58.00 $-11.00 0.00
2008-06-30 49.80 $-11.60 0.00
2008-03-31 53.20 $-11.20 0.00
2007-12-31 66.60 $-11.40 0.00
2007-09-30 71.80 $-10.40 0.00
2007-06-30 58.00 $-9.00 0.00
2007-03-31 51.80 $-8.40 0.00
2006-12-31 82.00 $-7.80 0.00
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $17.281B $0.476B
NOVAVAX INC is a specialty biopharmaceutical company engaged in the research, development and commercialization of proprietary products focused on women's health and infectious diseases. Their technology platforms involve the use of proprietary, microscopic, organized, non-phospholipid structures as vehicles for the delivery of a wide variety of drugs and other therapeutic products, including certain hormones, anti-bacterial and anti-viral products and vaccine adjuvants.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.660B 8.90
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.482B 21.14
Biohaven Pharmaceutical Holding (BHVN) United States $8.764B 0.00
Emergent Biosolutions (EBS) United States $2.892B 6.98
Arcus Biosciences (RCUS) United States $2.573B 0.00
Myovant Sciences (MYOV) United Kingdom $2.051B 0.00
ADC Therapeutics SA (ADCT) Switzerland $2.021B 0.00
Zymeworks (ZYME) Canada $1.443B 0.00
Ambrx Biopharma (AMAM) United States $0.527B 0.00
SQZ Biotechnologies (SQZ) United States $0.417B 0.00
Enzo Biochem (ENZ) United States $0.172B 50.71